Comparison of mangafodipir trisodium- and ferucarbotran-enhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients.
OBJECTIVE
The purpose of our study was to evaluate the validity of mangafodipir trisodium-enhanced versus ferucarbotran-enhanced MRI in the detection and characterization of hepatic lesions in colorectal cancer patients.


METHODS
Forty-one patients who were known to have or suspected of having hepatic metastasis from colorectal carcinoma underwent mangafodipir trisodium- or ferucarbotran-enhanced MRI in block randomization methods. Two radiologists independently reviewed the MR images to determine the number of hepatic lesions and to characterize the lesions as malignant or benign. Each lesion was assessed according to its size (small, <or= 2 cm; large, > 2 cm in diameter) on both mangafodipir trisodium- or ferucarbotran-enhanced MRI. The data were correlated with the reference diagnosis: histopathology and intraoperative sonography (n = 16); intraoperative sonography (n = 4); and imaging and clinical diagnosis with follow-up (> 3 months; n = 21). The detection rates and diagnostic accuracies of hepatic lesions on both sets of MR images were assessed using Fisher's exact test.


RESULTS
Eighty-two hepatic lesions (53 metastatic and 29 benign) were identified in 41 patients. No significant differences were seen between mangafodipir trisodium- and ferucarbotran-enhanced MRI for detecting all hepatic lesions (p = 0.183), small hepatic lesions (p = 0.299), all metastases (p = 0.695), and small metastases (p = 0.689). The diagnostic accuracies of mangafodipir trisodium- and ferucarbotran-enhanced MRI showed no significant differences in all hepatic lesions (p = 0.624) and small hepatic lesions (p = 0.641).


CONCLUSIONS
Mangafodipir trisodium- and ferucarbotran-enhanced MRI are similar in hepatic lesion detection and characterization in colorectal cancer patients.
Department of Radiology, University of Ulsan-Asan Medical Center, 388-1 Pungnap-dong, Songpa-gu, Seoul 138-736, South Korea.
Hyoung Jung
HJ
Kim
Kyoung Won
KW
Kim
Jae Ho
JH
Byun
Hyung Jin
HJ
Won
Yong Moon
YM
Shin
Pyo Nyun
PN
Kim
Moo-Song
MS
Lee
Moon-Gyu
MG
Lee
D000328:Adult; D000368:Aged; D015179:Colorectal Neoplasms / Q000473:pathology*; D003287:Contrast Media; D003911:Dextrans; D004492:Edetic Acid / Q000031:analogs & derivatives*; D005260:Female; D052203:Ferrosoferric Oxide; D006801:Humans; D007501:Iron; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000556:secondary*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles; D008297:Male; D008875:Middle Aged; D010087:Oxides; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives*
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; D011732:Pyridoxal Phosphate; D004492:Edetic Acid; D007501:Iron; C065507:ferumoxides; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid; D052203:Ferrosoferric Oxide